Table 1.
MCF7 cells were treated with Lugol's iodine solution or vehicle alone for 48 hr (see Methods and Materials for details). RNA was isolated and subjected to Microarray Analysis (see Methods and Materials for details). 29 genes were upregulated ≥ 2.0-fold (A) and 14 genes were down regulated ≥ 2.0-fold (B) in response to treatment. Genes were than clustered into functional categories using the DAVID Bioinformatics Database Gene Functional Classification Tool (NIAID/NIH). The fold change in expression is relative to control cells. Bold genes were verified by qRT-PCR (Figure 2).
A. 29 Genes that are Up-Regulated1 in Response to Iodine Treatment2 | |||
---|---|---|---|
Cell Cycle/Proliferation | Fold Change | ||
NM_001673 | ASNS | asparagine synthetase | 4 |
L24498 | GADD45A | growth arrest and DNA-damage-inducible, alpha3 | 2 |
Steroid Metabolism | |||
NM_000104 | CYP1B1 | cytochrome P450, family 1, subfamily B, polypeptide 13 | 11.3 |
NM_001353 | AKR1C1 | aldo-keto reductase family 1, member C13 | 6 |
NM_000499 | CYP1A1 | cytochrome P450, family 1, subfamily A, polypeptide 13 | 2.5 |
Transcription | |||
NM_003900 | SQSTM1 | sequestosome 1 | 2.8 |
AB025432 | TSC22D3 | delta sleep inducing peptide, immunoreactor | 2.6 |
DNA repair | |||
NM_019058 | DDIT4 | DNA-damage-inducible transcript 4 | 2.2 |
L24498 | GADD45A | growth arrest and DNA-damage-inducible, alpha3 | 2.0 |
Lipid Metabolism | |||
NM_000693 | ALDH1A3 | aldehyde dehydrogenase 1 family, member A3 | 3.2 |
NM_004315 | ASAH1 | N-acylsphingosine amidohydrolase (acid ceramidase) 1 | 2.2 |
tRNA synthesis | |||
NM_004184 | WARS | tryptophanyl-tRNA synthetase | 3 |
NM_002047 | GARS | glycyl-tRNA synthetase | 2.3 |
NM_003680 | YARS | tyrosyl-tRNA synthetase | 2 |
Other | |||
NM_021158 | TRIB3 | tribbles homolog 3 (Drosophila) | 4 |
NM_005218 | DEFB1 | defensin, beta 1 | 3.3 |
NM_033197 | C20orf114 | chromosome 20 open reading frame 114 | 2.7 |
NM_004753 | DHRS3 | dehydrogenase/reductase (SDR family) member 3 | 2.7 |
NM_002083 | GPX2 | glutathione peroxidase 2 (gastrointestinal) 3 | 2.5 |
NM_006636 | MTHFD2 | methylene tetrahydrofolate dehydrogenase | 2.5 |
AF104032 | SLC7A5 | solute carrier family 7, member 5 | 2.4 |
NM_004864 | GDF15 | growth differentiation factor 15 | 2.2 |
NM_000416 | IFNGR1 | interferon gamma receptor 1 | 2.1 |
NM_002356 | MARCKS | myristoylated alanine-rich protein kinase C substrate | 2.0 |
Function Unknown | |||
AK001064 | LOC86026 | hypothetical protein DKFZp434P055 | 3.5 |
AK054816 | ORAOV1 | oral cancer overexpressed 1 | 3.0 |
NM_006470 | TRIM16 | tripartite motif-containing 16 | 2.4 |
AF245505 | MXRA5 | matrix-remodelling associated 5 | 2.3 |
AL162069 | LOC144501 | hypothetical protein LOC144501 | 2.2 |
BE884686 | LTB4DH | leukotriene B4 12-hydroxydehydrogenase | 2.1 |
B. 14 Genes that are Down-Regulated4 in Response to Iodine Treatment2 | |||
---|---|---|---|
Estrogen responsive genes | Fold Change | ||
NM_003225 | TFF1 | trefoil factor 1 (estrogen-inducible sequence) 3 | -2.3 |
NM_003881 | WISP2 | WNT1 inducible signaling pathway protein 23 | -2.4 |
Cell Cycle genes | |||
NM_003258 | TK1 | thymidine kinase 1, soluble | -3.7 |
NM_002305 | LGALS1 | lectin, galactoside-binding, soluble, 1 (galectin 1) | -2.6 |
NM_007019 | UBE2C | ubiquitin-conjugating enzyme E2C | -2.5 |
NM_001071 | TYMS | thymidylate synthetase | -2.3 |
NM_053056 | CCND1 | cyclin D1 (PRAD1: parathyroid adenomatosis 1) 3 | -2.0 |
NM_002466 | MYBL2 | v-myb myeloblastosis viral oncogene homolog like 23 | -2.2 |
Cell Growth/Proliferation Genes | |||
NM_005264 | GFRA1 | GDNF family receptor alpha 13 | -2.5 |
NM_007161 | LST1 | leukocyte specific transcript 1 | -2.5 |
Ion Transport Genes | |||
NM_004669 | CLIC3 | chloride intracellular channel 3 | -2.2 |
Chromatin Organization | |||
NM_002105 | H2AFX | H2A histone family, member X | -2.2 |
Function Unknown | |||
NM_007173 | PRSS23 | protease, serine, 23 | -3.7 |
NM_006408 | AGR2 | anterior gradient 2 homolog (Xenopus laevis) | -2.1 |
1 Increase ≥ 2.0-fold relative to control
2 Accession number is to left, followed by gene symbol, name, and fold change.
3 Verified by QRT-PCR
4 Decrease ≥ 2.0-fold relative to control